What Is Bristol-Myers Squibb Company (BMY) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Bristol-Myers Squibb Company's intrinsic value is estimated at $109.61, presenting a divided outlook at the current price of $59.37. With an average implied return of +84.6% across a split 6–4 (bull–bear) consensus, the model spread of +443.1% underscores analytical uncertainty. Notably, RCMH-DCF sees the most upside at +371.4% (fair value: $279.88), while Sentiment SOTP is the most conservative at -71.6% ($16.84). The spread between these extremes — +443.1% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About BMY?
12 of 13 models are currently active for BMY. Of these, 7 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates BMY's intrinsic value at $265.38, implying +347.0% upside from the current price. See which stocks rank higher →
How Does BMY Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, BMY ranks #17 by Quality of Company score. CirclFi's QOC score of 9.0/10 evaluates 32 fundamental signals. A score of 9.0 places BMY in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Bristol-Myers Squibb Company's positioning within the Pharmaceutical Preparations segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.
Is BMY a Value Trap?
CirclFi's Value Trap algorithm assigns BMY a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Bristol-Myers Squibb Company. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Bristol-Myers Squibb Company scores 9.0 out of 10 on our 32-signal quality assessment, a elite rating that ranks among the highest-quality businesses in our coverage universe. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +443.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BMY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BMY's 12 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad